The Lived Experience of People With Von Willebrand Disease
NCT ID: NCT06064643
Last Updated: 2025-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
611 participants
OBSERVATIONAL
2023-12-08
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The Haemnet vWD360 programme is a mixed-methods, natural history study designed to gain a greater understanding of vWD and its impact on individuals and their families. It comprises both qualitative and quantitative approaches and is designed to include the perspectives of individuals with a diagnosis of any subtype of vWD.
The vWD360 study includes three components:
* Quantitative cross-sectional survey
* Qualitative one-to-one interviews with affected individuals
* 30-day bleed diary.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease
NCT04282486
Examining the Experiences of Children With Blood Disorders
NCT04600609
Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
NCT06014320
Perioperative Modification of Hemostasis During Ventricular Assist Device Implantation
NCT03966313
Safety and Efficacy of WoundClot Surgical
NCT06696092
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Type 1: a quantitative defect characterised by decreased levels of vWF in the circulation. Many affected individuals have a mild bleeding phenotype but may have heavy menstrual bleeding (HMB) and bleed following trauma/surgery.
* Type 2: a qualitative defect that is further divided into four subtypes
* Type 2A - vWF is unable to bind to form the large vWF multimers required for coagulation
* Type 2B - vWF has enhanced binding to platelet glycoprotein Ib (GPIb), causing rapid clearance of platelets and an associated thrombocytopenia
* Type 2M - vWF has a decreased ability to bind to GPIb
* Type 2N - there is a deficiency of vWF binding to FVIII
* Type 3: the most severe vWD subtype, characterised by complete absence of vWF production and an inability to bind with FVIII, resulting in a severely reduced FVIII level.
Acquired vWD can develop as an autoimmune disorder, as a result of cancer, some cardiac conditions or following of certain drugs. It will not be considered as part of this study.vWD is characterized by prolonged or spontaneous bleeding from birth. Affected individuals tend to bruise easily, may have frequent nosebleeds (epistaxis), may bleed from the gums, bleeding within tissues (haematoma), in the gastrointestinal tract (more common later in life) and joint bleeds (in Type 3). vWD causes prolonged bleeding following injury, trauma, or surgery (including dental work). Women with vWD can have prolonged heavy menstrual bleeding, they may also have an increased risk of excessive blood loss during pregnancy and childbirth.
The severity and frequency of the bleeding episodes in vWD can vary greatly among affected individuals, even within the same family. The bleeding phenotype correlates to some degree with the subtype of VWD, with those with the severest form (Type 3) having the most bleeding.
Treatment varies based on the diagnosis. In Types 1 and 2 vWD treatment is usually 'on-demand' (after bleeding occurs) with some patients receiving prophylaxis if they have significant frequent bleeding. On demand treatment may be with oral, intra-nasal or subcutaneous treatments or with intravenous infusions of clotting factor concentrates containing FVIII/vWF. This is the method of treatment for all bleeding and prophylaxis in Type 3 vWD, where for some patients, treatment may be given at home.
The lack of routine prophylaxis in Type 1 and 2 vWD means that most patients are reliant on hospital delivered care, which may involve frequent clinic appointments, causing prolonged bleeding due to a lack of timely administration of treatment. This can result in concurrent illnesses such as iron deficiency anaemia, which further impacts on the quality of life of affected individuals and their families.
There remains a need for a comprehensive understanding of the experience of people with vWD across the whole spectrum of subtypes in order to identify:
* The nature and range of symptoms that people experience and how these vary with the different disease subtypes
* The variability in pathways through which patients progress to access appropriate care
* The impact of living with vWD on the individual's quality of life.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Survey Arm
All participants will be asked to complete an online survey
Online Survey
All participants will be asked to complete an online survey
Interview Arm
A sample of the survey group will be asked to take part in a single qualitative interview
Qualitative Interview
30 survey participants will take part in a single one-hour qualitative interview.
Bleed Diary Arm
A sample of the survey group will be asked to take part in a 30 day bleed diary
Bleed Diary
50 participants will complete a 30 day bleed diary
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Online Survey
All participants will be asked to complete an online survey
Qualitative Interview
30 survey participants will take part in a single one-hour qualitative interview.
Bleed Diary
50 participants will complete a 30 day bleed diary
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For the qualitative interview-based substudy, 30 adults who have completed the survey and who wish to be interviewed will be purposively selected for a broad range of ages and diagnostic subtype.
* For the bleed diary substudy, 50 adults who have completed the survey and who wish to take part will be purposively selected for a broad range of ages and diagnostic subtype.
Exclusion Criteria
* Have other inherited bleeding disorders
* Do not wish to participate in or to consent to the study.
Those for whom written/spoken English would prohibit participation will also be excluded.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hemab ApS
INDUSTRY
Haemnet
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Simon Fletcher, MA
Role: PRINCIPAL_INVESTIGATOR
Haemnet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oxford University Hospitals NHS Foundation Trust
Oxford, Oxfordshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
v1.0 dated 15 June 2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.